One patient's long journey with a type of lung cancer that spread to the spine
Original title: Advanced ALK-EML4 fusion-positive non-small cell lung cancer with intraspinal metastases: a case report.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This describes what happened to one patient, not a tested treatment plan.
The short version
This report tells the story of one person whose lung cancer spread inside the spine and who lived for many years with treatment.
What was studied. Doctors wrote about one patient with a type of lung cancer that has a gene change called ALK-EML4. The cancer spread inside the spinal canal, which is rare.
What they found. Early gene tests did not find the ALK change. A more detailed test at the third return of the cancer did find it. After the fifth return, the patient had radiation, then two targeted drugs, lorlatinib and anlotinib, and then stayed on lorlatinib alone. The patient had lived 121 months at the time of the report and had been on lorlatinib for 48 months.
What this means, and what it doesn't
What it could mean: If a gene test comes back empty, testing again later with a more detailed test may find a change that a drug can target. It also shows that some people with this cancer can live a long time, even after it comes back many times.
What it doesn't mean: This is the story of just one person. It does not show that this drug mix will work for others. It was not a trial, and it does not change everyday care on its own. It is not a cure.
Source: PubMed, September 3, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.